Intellective Suzhou

About Intellective Suzhou

Intellective Suzhou, legally registered as Intellective Biologics (Suzhou) Co., Ltd., operates as a contract development and manufacturing organization (CDMO) in the biopharmaceutical sector. Established in April 2018 by Founder and CEO Li Zhi, the company is strategically located in the biotech hub of Suzhou, China. The firm's business model is centered on providing comprehensive, one-stop services to pharmaceutical and biotech companies, guiding their products from initial DNA stages through to Investigational New Drug (IND) and Biologics License Application (BLA) submissions. Intellective Bio generates revenue by offering these integrated development and production services, positioning itself as a pure-play CDMO that does not develop its own proprietary products.

The company has demonstrated significant growth, backed by substantial investor confidence. It secured an undisclosed Series A round in December 2020 from investors including Legend Capital and BioTrack Capital. This was followed by a Series B financing in August 2021 and a major Series C funding round in August 2022, which raised over $74 million (500 million yuan) led by Gaorong Capital and CTS Capital. These funds have been allocated towards expanding commercial production capacity, upgrading technological platforms, and advancing its international operations. Since its inception, Intellective Bio has signed agreements with hundreds of clients and achieved profitability, with reported revenues in the hundreds of millions of yuan in 2021.

Intellective Bio provides a wide array of services focused on macromolecular biopharmaceuticals. Its expertise covers the development and manufacturing of antibodies, antibody-drug conjugates (ADCs), fusion proteins, and other recombinant proteins. The company operates multiple cGMP (current Good Manufacturing Practice) facilities in Suzhou's Xiangcheng District, Suzhou Industrial Park (SIP), and Changshu, designed to comply with regulations in the US (FDA), Europe (EMA), and China (NMPA). These sites offer flexible production scales, with bioreactor capacities ranging from small research volumes up to large-scale commercial production, with a projected total capacity of 220,000 liters by 2023. The company’s service platforms include cell line development, upstream and downstream process development, analytical science, and aseptic fill-finish services, enabling it to support clients throughout the entire product lifecycle.